Clinical trials: Nab-paclitaxel
Metastatic Solid Tumor
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2.
- Trial name
- TACTIC-3 (NCT05862324)
- Testing
- TAC01-CLDN18.2
- Where
- 9 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Triumvira Immunologics, Inc.
Metastatic Pancreatic Adenocarcinoma
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Gemcitabine and nab-paclitaxel is a standard regimen (NCCN, Category 1) for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). However, further improvement in treatment is needed.
- Trial name
- NCT02562898
- Testing
- Ibrutinib, Paclitaxel, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Margaret Tempero
Breast Cancer, Peripheral Neuropathy
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
- Trial name
- NCT04675450
- Testing
- NBP Softgel Capsules
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
This phase II trial is studying how well ABI-007 works in treating patients with persistent or recurrent cervical cancer. Drugs used in chemotherapy, such as ABI-007, work in different ways to stop the growth of tumor cells…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00309959
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Laboratory Biomarker Analysis
- Where
- 26 sites in United States
- Volunteers
- 37 people
- Sponsor
- Gynecologic Oncology Group
Gastric Adenocarcinoma
Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients
Gastric cancer have poor prognosis and majority of patients resistant to 5-FU/DDP based first-line chemotherapy in China. There was no recommended second-line chemotherapy for advanced gastric cancer.
- Trial name
- NCT01336062
- Testing
- Nanoparticle Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Peking University
Nasopharyngeal Cancer
Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study
Neoadjuvant chemotherapy followed by concurrent chemoradiation (CCRT) has been recommended in the treatment of locoregionally-advanced nasopharyngeal carcinoma (NPC), with docetaxel, cisplatin (DDP) and 5-fluorouracil (5-Fu)…
- Trial name
- NCT04850235
- Testing
- Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer
Targeting tumor stroma is emerging as a strategic approach for pancreatic cancer treatment. Actually, one of the most interesting characteristics of pancreatic cancer is the dense fibrotic stroma surrounding tumor cells.
- Trial name
- NCT01442974
- Testing
- Gemcitabine plus nab-paclitaxel
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Grupo Hospital de Madrid
Carcinoma, Non-small Cell Lung
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
This study will enroll elderly patients with advanced non-small cell lung cancer who are at high risk of developing chemotherapy toxicity (side effects).
- Trial name
- NCT02590003
- Testing
- Carboplatin, Nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Yale University
Biliary Tract Cancer, Cholangiocarcinoma
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in…
- Trial name
- PURITY (NCT06037980)
- Testing
- Gemcitabine, Nab paclitaxel, Cisplatin
- Where
- 19 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Ovarian Cancer
Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer
The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.
- Trial name
- NCT06815497
- Testing
- Telmisartan
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Tyler J Curiel
Pancreatic Cancer
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR6390 in combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with advanced/metastatic pancreatic cancer.
- Trial name
- NCT05185869
- Testing
- SHR6390, Nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Ruijin Hospital
Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations.
- Trial name
- AURORAS-1 (NCT06983743)
- Testing
- ERAS-0015, ERAS-0015 in combination
- Where
- 9 sites in United States
- Volunteers
- 600 people
- Sponsor
- Erasca, Inc.
Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
The goal of this clinical trial is to learn if add SHR-A1811 and/or Adebrelimab on standard chemotherapy could further improve the pCR rate in HR+/HER2 low early stage breast cancer patients.
- Trial name
- NCT07317778
- Testing
- SHR-A1811, Adebrelimab (PD-L1 inhibitor), Taxane Chemotherapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Non Small Cell Lung Cancer
Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC
The aim of the study was to investigate the efficacy of Toripalimab Combined with Double Platinum Based Chemotherapy for Initially Unresectable Non-driver Gene Mutation Non-small Cell Lung Cancer.
- Trial name
- TOGATHER (NCT04144608)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yongchang Zhang
Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
This phase II trial studies how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma).
- Conditions
- Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT03579771
- Testing
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Emory University
Pancreatic Cancer
A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer
This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy…
- Trial name
- NCT02873598
- Testing
- FOLFIRINOX or gemcitabine/abraxane, SBRT
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Colorado, Denver
Pancreatic Cancer
Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel
This was a quality of life (QOL) study done in the context of a randomized trial in locally advanced or metastatic pancreatic cancer.
- Trial name
- QOLINPAC (NCT02106884)
- Testing
- Nab-paclitaxel, Gemcitabine
- Where
- 18 sites in Belgium
- Volunteers
- 146 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with…
- Trial name
- NCT07111832
- Testing
- SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC)
Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric…
- Conditions
- Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC), Ascites, Malignant
- Trial name
- NCT07855640
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients
This study combines canakinumab (ACZ885), a high-affinity human anti-interleukin-1β (IL-1β) monoclonal antibody (mAb), and spartalizumab (PDR001), a mAb directed against human Programmed Death-1 (PD-1), with the chemotherapy…
- Trial name
- PanCAN-SR1 (NCT04581343)
- Testing
- Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pancreatic Cancer Action Network